麻豆传媒

Dr Jennifer M. Yeh is a decision scientist whose research focuses on improving health outcomes at the population level. She is an Assistant Professor of Pediatrics at Harvard Medical School and Boston Children’s Hospital. Dr Yeh has an M.S. in Health Policy and Management from the Harvard T.H. Chan School of Public Health and a PhD in Health Policy from Harvard University. She has extensive experience applying decision-analytic modelling and cost-effectiveness analysis methods to evaluate clinical guidelines and inform health policy. Her research identifies opportunities to improve cancer control efforts spanning across the cancer continuum from prevention to survivorship. She is funded by the National Cancer Institute (NCI), the National Institute of Child Health and Human Development (NICHHD), and the American Cancer Society (ACS).

Cheryl London, D.V.M., Ph.D., ACVIM, is the Anne Engen and Dusty Professor of Comparative Oncology and associate dean for research and graduate education at Cummings School of Veterinary Medicine. London joined Tufts in 2016. She is director of Clinical Research Shared Resource, which oversees studies in client-owned animals at Cummings School.
London oversees the Research Collaboration Team at the Tufts Clinical Translational Science Institute, working to catalyze broadly engaged team science. She is a research professor at the School of Medicine and is a member of the Immunology Graduate Program at the Graduate School of Biomedical Sciences. London has ongoing collaborations with the Broad Institute, UMass Chan Medical School, Tufts Medical Center, MIT, and Tufts School of Medicine, as well as several projects with industry partners. These include immuno-oncology studies in the setting of osteosarcoma, and diffuse large B cell lymphoma and soft tissue sarcoma that involve spontaneous cancer in dogs to study novel strategies aimed at altering the tumor microenvironment and utilizing unique small molecule/immunotherapy combinations.
London earned her D.V.M. at Cummings School, completed her residency in medical oncology at the University of Wisconsin-Madison, and received her Ph.D. in immunology at Harvard University, where she was also a postdoctoral fellow in the Department of Pathology. Prior to joining Cummings School London was the Shackelford Professor at The Ohio State University’s College of Veterinary Medicine and assistant professor at the University of California, Davis School of Veterinary Medicine.

Daniel King, MD, PhD, is a former Howard Hughes research scholar at the National Institutes of Health and trained in genomics and bioinformatics at the Wellcome Trust Sanger Institute, where he developed software tools to perform mosaic copy number detection. During his time at the Wellcome Trust Sanger Institute, he spearheaded copy number analysis for 36,000 exome samples in the Deciphering Developmental Disorder Rare Disease project. The results from this work characterized unprecedented detail in the landscape and architecture of developmental disorders, was published in Nature and Lancet, and led to several first author publications.
Following medical and graduate school, Dr. King pursued a medical oncology fellowship under the ABIM Research Track pathway at Stanford University. A core focus of his fellowship research involved circulating tumor DNA (ctDNA), which included the computational design of a ctDNA detection panel for pancreas cancer and laboratory validation. This work extended to fragmentomics—a computational analysis of circulating DNA fragment ends as a biomarker of cancer for early detection. From here, Dr. King created a large biobank of pancreas cancer specimens consisting of nearly 500 clinical blood samples from approximately 250 patients. He went on to link this biobank with a large clinical research database built in pancreatic cancer to mine and associate clinical data with translational correlates.

 has over two decades of educational and professional experience serving college students with disabilities.
Sears is the director of Beckwith Residential Support Services and the assistant director of academic services with the  at the University of Illinois Urbana-Champaign. She holds a Ph.D. in community health with a rehabilitation emphasis from the University of Illinois and is currently a research assistant professor of kinesiology and community health. She is a researcher at the . 
Key research areas

Factors impacting the career readiness of college students with disabilities
Empathic design methodology and its impacts on overall quality of life outcomes for everyday living
Emerging adulthood and disability identity

Notable Honors, Awards, Affiliations: 

University of Illinois Emerging Women Leaders - Nominee, 2022-2023
Outstanding BSW Field Education Instructor Award for the 2017-2018 academic year -  School of Social Work, University of Illinois at Urbana Champaign, April 2018
Recipient of the Robert Greenberg for Innovation Award - 4th Annual Career Opportunities for Students with Disabilities (COSD) conference, Northbrook, IL, November 2013
Recipient of the Chancellor’s Academic Professional Excellence (CAPE) Award, University of Illinois at Urbana Champaign, April 2012
Association of Higher Education & Disability (AHEAD)

 is a professor in the  and The Neuroscience Program at the University of Illinois Urbana-Champaign and a researcher at the .
Mischkowski earned his Ph.D. in psychology at The Ohio State University and conducted postdoctoral research at the National Institutes of Health. He joined Illinois in 2024.
His research is located at the intersection between physical pain and social affect and behavior (e.g., empathy, aggression) through a multi-method approach, relying on social pharmacological intervention, psychophysiology and functional magnetic resonance imaging.
Research areas

Neuroscience of empathy and aggression
Physical pain
Emotional pain
Painkillers (especially acetaminophen)

I am a breast medical oncologist and serve as the Medical Co-Director for Cancer Survivorship and Translational Behavioral Science Program at the Sylvester Comprehensive Cancer Center. I am also the Associate Director of Community Outreach of the Breast Cancer Program at Sylvester-Plantation. Since graduating from a Hematology Oncology Fellowship in 2008, I dedicated my career exclusively to building expertise in breast cancer prevention, treatment, and survivorship. Immediately after my fellowship, I joined Memorial Cancer Institute in Broward County, where I had the privilege to participate in several committees focused on patient satisfaction and quality improvement.

My goal was always to provide outstanding care that not only offers standard treatments but participation in vital clinical trials that offer patients innovative treatments before their approval. I served as a member of the local IRB for 8 years prior to 2015, when I joined University of Miami. Since joining our institution, I was invited to become a PRMC member and a member of Social Behavior committee. I value this committee and their role of making sure best research is available to our patients, not only scientifically but also ethically. I am committed to bringing new trials to our Breast Cancer Program and I am serving as a Principal Investigator on more than 10 clinical trials at the present time. I am the chair-elect for the ASCO lead TAPUR clinical trial and the local PI for TAPUR.

I have worked closely with Dr. Crane and her team on this application entitled, Comparative Effectiveness of Lifestyle Interventions for Older Cancer Survivors and Their Caregivers: the VITALITY Trial and will serve as Co-Investigator for this study. I will serve as a champion for this study for recruitment and provide my clinical oncology expertise in breast cancer to address participant related issues that may arise during this study including determining patient eligibility on a case by case basis, participate in regular research meeting, data interpretation and dissemination of findings.

Coral Olazagasti, MD is an assistant professor at the Sylvester Cancer Center, University of Miami at Miami, Florida. Dr. Olazagasti developed an interest in lung cancer screening while witnessing that the majority of new referrals during an outpatient oncology elective presented with advanced stages of lung cancer. Being a Latina physician, she is personally invested in ethnic and racial disparities in the medical field and has drawn on her own experiences to highlight the inequities and barriers that minority patients face in healthcare. She hopes to continue to expand her research passions and help close the gap for minorities and vulnerable populations.

---

---

Dr. Pongas is a board certified hematologist and oncologist with clinical experience in indolent and aggressive lymphomas. His research interest is the development of cancer therapeutics for B cell lymphomas and viral associated lymphomas. He has done significant laboratory work in Diffuse Large B cell lymphoma elucidating the therapeutic role of inhibiting various PI3K isoforms. He collaborates with clinical scientists to develop novel therapies in lymphomas and with laboratory scientists to study the mechanism of resistance to the therapies and ways to bypass it. With this approach he hopes to develop combinational therapies and increase the cure rates of various lymphomas.

Jonathan C. Trent, MD, PhD, is professor of medicine, associate director for clinical research, and director of the Bone and Soft-tissue Sarcoma Group at the Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL. He earned his undergraduate degree in chemistry at Southeastern Oklahoma State University and his MD and PhD in cancer biology from The University of Texas Health Science Center. He completed an internship and residency in internal medicine at The University of Texas Health Science Center and a fellowship in medical oncology at The University of Texas MD Anderson Cancer Center while serving as chief fellow. Prior to joining the University of Miami Miller, he held appointments as faculty of The University of Texas Graduate School of Biomedical Sciences at Houston and associate professor of medicine in the Department of Sarcoma Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston.

Dr. Merchan is a tenured Professor of Medicine in the division of Medical Oncology. He is the Co-leader of the Translational and Clinical Oncology Research Program, the Director of the Phase 1 Clinical Trials Program, and the Associate Director of the NIH funded Calabresi Clinical Oncology Research Career Development Award. As a physician scientist, his contributions to science include redefining the role of the plasminogen activator system in cancer progression, the development of novel preclinical and clinical strategies to overcome resistance in RCC and angiogenesis dependent cancers, and the preclinical and clinical development of tumor and stromal targeted oncolytic viruses and virus-drug combinations. He leads the only academic phase I program in South Florida, bringing novel treatment strategies to many patients with advanced cancer. Dr. Merchan has an established track record in translational cancer research, bringing lab discoveries to the clinic, and has been involved in the development of novel, effective treatment strategies in genitourinary cancers, which resulted in practice changing publications and introduced new treatment options for cancer patients.

Dr. Andrei Nikiforchin is a dedicated surgical oncologist, who graduated from the First Pavlov State Medical University in St. Petersburg, Russia, and further trained across Europe and the United States. He has distinguished himself in various roles, including a Clinical Researcher in Surgical Oncology at Mercy Medical Center in Baltimore, MD, a Medical Writer and Editor at "OncoWiki", and an Expert Consultant at "Prosto Sprosit'". Renowned for his surgical expertise and significant contributions to oncology research, Dr. Nikiforchin has authored multiple peer-reviewed publications. His experience is further amplified by his active participation in various professional consortiums and societies, commitment to community-oriented initiatives, and proficiency in English, Ukrainian, and Russian.
Andrei Nikiforchin, M.D., is a GCP-certified researcher in the Surgical Oncology Department of The Institute for Cancer Care at Mercy Medical Center in Baltimore, Maryland, USA. He received his medical doctor degree at Pavlov First State Medical University in St. Petersburg, Russia, in 2015, and then got two specialties in general surgery and surgical oncology. In 2018 after finishing his work in Clinical Hospital #1 MEDSI in Moscow, Russia, Dr. Nikiforchin moved to the United States and started research at The Institute for Cancer Care at Mercy Medical Center in Baltimore, Maryland. His areas of interest and investigation include gastrointestinal and neuroendocrine tumors, peritoneal surface malignancies, and cytoreductive surgery. Dr. Andrei Nikiforchin is a member of ASCO and SSO since 2019 and RUSSCO since 2021.

Dr. Panayotis Ledakis is an oncologist in Baltimore, Maryland and is affiliated with multiple hospitals in the area, including  and . He received his medical degree from University of Athens and has been in practice for more than 20 years. Dr. Panayotis Ledakis has expertise in treating lymphoma, small intestine/colorectal cancer, prostate cancer, among other conditions - see all areas of . Dr. Panayotis Ledakis accepts Medicare, Aetna, Cigna, United Healthcare - see other . Dr. Panayotis Ledakis is highly recommended by patients.

I graduated from the Government Medical College, Trivandrum, India and then completed my Internal Medicine residency at the University of Arkansas for Medical Sciences, Little Rock.
I am interested in solid tumors with a focus on clinical research in breast cancer, genitourinary malignancies, and neuroendocrine tumors.
My goal is to become an academic physician and lead a research-focused career. Interesting Facts: I am trained in Indian classical dancing, and I love gardening.
I am a hematology and oncology fellow at the Roswell Park Comprehensive Cancer Center. I am actively involved in clinical research in oncology and medicine. My main interest is solid tumor malignancies with a focus on breast cancer and genitourinary malignancies. I am interested in health outcomes research, quality of life, immunotherapy and targeted agents, tumor microenvironment studies, and the development of newer therapeutics.

Bailey Loving, originally from Denver, Colorado, embarked on his academic journey in molecular biology at The University of Denver, where he developed an early interest in radiation biology. He then completed his medical doctorate at the University of Colorado, where he further pursued his interest in oncology. Currently training at Beaumont, Bailey is dedicated to enhancing his skills in using diverse radiation modalities for complex cases and is keen on integrating basic science research with clinical applications. Outside of his professional endeavors, he enjoys wildlife photography, canoeing in the Great Lakes, spending time with his fiancé, playing the piano, playing video games, and continually learning new things. Additionally, Bailey takes pleasure in coding, wildlife photography (Instagram @drlovingphotography), playing with his mini Goldendoodle, Guinea, and playing ping pong.

Shipra Gandhi, MD is an Assistant professor of oncology at the Roswell Park Comprehensive Cancer Center. She completed her fellowship in hematology and oncology at Roswell Park Comprehensive Cancer Center, Buffalo, NY and recieved her board certification from the American Board of Internal Medicine.
For medical oncologist and researcher , Assistant Professor of Oncology specializing in breast cancer in the Department of Medicine at Roswell Park Comprehensive Cancer Center, the path to physician-scientist was clear from the very beginning.
“I was raised in a family of physicians. Both my parents are doctors, and I grew up listening to their conversations about managing difficult cases, so I was very interested in the field of medicine from an early age,” says Dr. Gandhi, who was born and raised in India. Dr. Gandhi attended the prestigious Lady Hardinge Medical College in New Delhi and worked on a project funded by the Indian Council of Medical Research that investigated advanced methods of tuberculosis detection. “I knew from the very beginning that I wanted to become a doctor. But I was also interested in new discoveries, so I knew that in addition to taking care of patients, I somehow wanted to be actively involved in research to move the field forward.”

---

---

---